Study to Compare Efficacy, Safety, and Immunogenicity of LUBT010 (Proposed Ranibizumab Biosimilar) and Lucentis® in Patients With Neovascular AMD

NCT ID: NCT04690556

Last Updated: 2026-01-29

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-14

Study Completion Date

2024-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a global, phase III, double blind, randomized controlled study to compare the efficacy, safety \& immunogenicity of LUBT010 with Lucentis® in patients with neovascular age-related macular degeneration.

Eligible patients will be randomly assigned in 1:1 ratio to receive once monthly intravitreal injection of LUBT010 or Lucentis® for 12 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neovascular Age-related Macular Degeneration

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Drug: LUBT010 (proposed ranibizumab biosimilar)

Group Type EXPERIMENTAL

LUBT010 (proposed ranibizumab biosimilar)

Intervention Type DRUG

LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly

Drug: Lucentis (ranibizumab)

Group Type ACTIVE_COMPARATOR

Lucentis (ranibizumab)

Intervention Type DRUG

Lucentis® 0.5 mg via intravitreal injection once monthly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LUBT010 (proposed ranibizumab biosimilar)

LUBT010 (proposed ranibizumab biosimilar) 0.5 mg via intravitreal injection once monthly

Intervention Type DRUG

Lucentis (ranibizumab)

Lucentis® 0.5 mg via intravitreal injection once monthly

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Ambulatory male or female participants with age ≥ 50 years at the time of screening
2. Capable of understanding and giving written informed consent
3. Primary or recurrent (anti-vascular endothelial growth factor naïve) active choroidal neovascularization (CNV) lesions involving the foveal center secondary to AMD
4. Best corrected visual acuity (BCVA) between 20/40 and 20/200 (Snellen equivalent) in the study eye, using ETDRS testing
5. Willingness and ability to undertake all scheduled visits and assessments

Exclusion Criteria

1. Known hypersensitivity to ranibizumab or any of the components of study medication
2. Known history of allergy to fluorescein dye
3. Scar, fibrosis, or atrophy involving the center of the fovea in the study eye
4. Subretinal hemorrhage in the study eye that involves the center of the fovea
5. Uncontrolled glaucoma
6. Use of prohibited treatments
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Lupin Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Retina-Vitreous Associates Medical Group

Beverly Hills, California, United States

Site Status

Bruce A. Segal, MD, PA

Delray Beach, Florida, United States

Site Status

Cumberland Valley Retina Consultants, P.C.

Hagerstown, Maryland, United States

Site Status

UPMC Eye Center - Eye and Ear Institute

Pittsburgh, Pennsylvania, United States

Site Status

Black Hills Regional Eye Institute

Rapid City, South Dakota, United States

Site Status

Valley Retina Institute

McAllen, Texas, United States

Site Status

Medical Center Oxycom EOOD

Burgas, , Bulgaria

Site Status

Eye medical center - Visus

Gorna Oryahovitsa, , Bulgaria

Site Status

University First MHAT-Sofia, St. Joan Krastitel EAD

Sofia, , Bulgaria

Site Status

MC Ophta-Nevro

Sofia, , Bulgaria

Site Status

Specialized Eye Hospital Pentagram

Sofia, , Bulgaria

Site Status

DCC Alexandrovska, EOOD

Sofia, , Bulgaria

Site Status

Military Medical Academy - MHAT

Sofia, , Bulgaria

Site Status

Specialized Hospital for Active Treatment of Ophthalmologic Diseases Zora, OOD

Sofia, , Bulgaria

Site Status

MHAT Trakia, EOOD

Stara Zagora, , Bulgaria

Site Status

Medical Center Vereya EOOD

Stara Zagora, , Bulgaria

Site Status

Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktato Korhaz

Győr, , Hungary

Site Status

The Eye Care Center

Guwahati, Assam, India

Site Status

Drishtipunj Eye Hospital Pvt Ltd

Patna, Bihar, India

Site Status

Advance Retina Care

Ahmedabad, Gujarat, India

Site Status

Sadguru Netra Chikitsalaya

Ahmedabad, Gujarat, India

Site Status

Netralaya - Super Speciality Eye Hospital

Ahmedabad, Gujarat, India

Site Status

Rising Retina Clinic

Ahmedabad, Gujarat, India

Site Status

Government Eye Hospital M & J Institute of Ophthalmology

Ahmedabad, Gujarat, India

Site Status

M & J Western Regional Institute of Ophthalmology

Ahmedabad, Gujarat, India

Site Status

P N Desai Eye Hospital

Ahmedabad, Gujarat, India

Site Status

Kanoria Hospital and Research Center

Gandhinagar, Gujarat, India

Site Status

Shivam Retina Clinic and Eye Hospital

Surat, Gujarat, India

Site Status

Kiran Hospital Multi Super Speciality Hospital & Research Centre

Surat, Gujarat, India

Site Status

Kashyap Memorial Eye Hospital Pvt. Ltd.

Ranchi, Jharkhand, India

Site Status

Nethra Eye Hospital

Bangalore, Karnataka, India

Site Status

Mysore Medical College and Research Institute

Mysore, Karnataka, India

Site Status

JSS Hospital

Mysore, Karnataka, India

Site Status

Regional Institute of Opthalmology

Trivandrum, Kerala, India

Site Status

Deshmukh Eye Hospital

Amravati, Maharashtra, India

Site Status

Kamalnayan Bajaj Hospital

Aurangabad, Maharashtra, India

Site Status

Aditya Jyot Eye Hospital Pvt. Ltd.

Mumbai, Maharashtra, India

Site Status

Shroff Eye Hospital & Vision Research Centre

Mumbai, Maharashtra, India

Site Status

Kenia Eye Hospital

Mumbai, Maharashtra, India

Site Status

Anideep Eye Hospital

Mumbai, Maharashtra, India

Site Status

Topiwala National Medical College & B. Y. L. Nair Charitable Hospital

Mumbai, Maharashtra, India

Site Status

Ambade Eye Hospital

Nagpur, Maharashtra, India

Site Status

Dhadiwal Hospital in Coalition with Shreeji Healthcare

Nashik, Maharashtra, India

Site Status

Vijay Vallabh Hospital and Medical Research Center

Pālghar, Maharashtra, India

Site Status

Dr. D. Y. Patil Medical College

Pune, Maharashtra, India

Site Status

Insight Institute of Ophthalmology

Pune, Maharashtra, India

Site Status

Sri Guru Ram Das Institute of Medical Sciences & Research

Amritsar, Punjab, India

Site Status

Advanced Eye Centre Post Graduate Institute of Medical Education & Research

Chandigarh, Punjab, India

Site Status

Dr.Agarwal's Eye Hospital

Tirunelveli, Tamil Nadu, India

Site Status

Dr. J L Rohatgi Memorial Eye Hospital

Kanpur, Uttar Pradesh, India

Site Status

King George's Medical University

Lucknow, Uttar Pradesh, India

Site Status

Sam Eye Hospital

Lucknow, Uttar Pradesh, India

Site Status

R.K.Netralaya Eye Hospital (P) Ltd.

Varanasi, Uttar Pradesh, India

Site Status

Regional Institute of Ophthalmology

Kolkata, West Bengal, India

Site Status

Dr. Shroff's Charity Eye Hospital

New Delhi, , India

Site Status

Sir Ganga Ram Hosptial

New Delhi, , India

Site Status

Aakash Healthcare Super Specialty Hospital

New Delhi, , India

Site Status

Szpital Świętego Łukasza S. A.

Bielsko-Biala, , Poland

Site Status

Specjalistyczny Osrodek Okulistyczny Oculomedica

Bydgoszcz, , Poland

Site Status

Prywatna Klinika Okulistyczna OFTALMIKA

Bydgoszcz, , Poland

Site Status

Provisus Badania Kliniczne Sp. z o.o.

Częstochowa, , Poland

Site Status

Clinical Medical Research Sp. z o.o.

Katowice, , Poland

Site Status

Gabinet Okulistyczny prof. Edward Wylegala

Katowice, , Poland

Site Status

ETG Lodz

Lodz, , Poland

Site Status

CaminoMed - Specjalistyczne Gabinety Lekarskie

Tarnowskie Góry, , Poland

Site Status

LLC HI Optic-Center

Chelyabinsk, , Russia

Site Status

RSHI State Novosibirsk Regional Clinical Hospital

Novosibirsk, , Russia

Site Status

BHI of Omsk region Clinical Ophthalmology Hospital n.a V.P. Vykhodtsev

Omsk, , Russia

Site Status

Standard Clinic Penza LLC

Penza, , Russia

Site Status

LLC X7 Clinical research

Saint Petersburg, , Russia

Site Status

Fakultna nemocnica s poliklinikou F.D. Roosevelta

Banská Bystrica, , Slovakia

Site Status

Nemocnica svateho Michala

Bratislava, , Slovakia

Site Status

Univerzitna nemocnica Bratislava, Nemocnica Ruzinov

Bratislava, , Slovakia

Site Status

Fakultna nemocnica s poliklinikou Nove Zamky

Nové Zámky, , Slovakia

Site Status

Nemocnica Poprad a.s.

Poprad, , Slovakia

Site Status

Nemocnica s poliklinikou Trebisov a.s.

Trebišov, , Slovakia

Site Status

Fakultna nemocnica Trencin

Trenčín, , Slovakia

Site Status

Fakultna nemocnica s poliklinikou Zilina

Žilina, , Slovakia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Bulgaria Hungary India Poland Russia Slovakia

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-004409-42

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

LRP/LUBT010/2016/008

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Lucentis in Advanced Macular Degeneration
NCT00896779 COMPLETED PHASE2
Lucentis KAV Study
NCT01570608 COMPLETED PHASE3